AstraZeneca e Bristol Myers Squibb stanno negoziando una fusione che creerebbe il quarto colosso farmaceutico mondiale con quasi 400 miliardi di dollari di capitalizzazione. I colloqui, riferiti dal Financial Times, potrebbero concludersi con un accordo, sebbene ritardi o fallimenti siano possibili.
AstraZeneca e Bristol Myers Squibb sarebbero in trattativa per una fusione che creerebbe il quarto colosso farmaceutico mondiale con una capitalizzazione vicina ai 400 miliardi di dollari, secondo quanto riportato dal Financial Times.
Eli Lilly is acquiring psychedelic drug maker AtaiBeckley for up to $3.8 billion, indicating Big Pharma's growing interest in these treatments for mental health. This follows positive clinical trial results and a Trump executive order to fast-track FDA reviews, despite past regulatory hurdles.
A study by CUHK Business School reveals that AI investment enhances business resilience, particularly for firms with limited budgets, by helping them recover faster from natural disasters. AI's effectiveness is greatest in optimizing supply chains and production inputs during crises.
The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.
Global biopharma M&A is accelerating in 2026, driven by patent cliffs and pipeline needs. Dealmaking has reached $106 billion, on track to exceed $250 billion, the highest since 2019. Strategic 'bolt-on' acquisitions under $5 billion dominate, with a growing interest in Chinese assets.
Thirty-one MPs have launched a parliamentary challenge against new powers granted to Health Secretary Wes Streeting, allowing him to dictate NHS drug spending thresholds. Critics argue the move undermines the independence of Nice and favors US pharmaceutical interests.
